目的:探讨微创胸腔置管内交替注射尿激酶、异烟肼和地塞米松治疗结核性胸膜炎的临床疗效.方法:选取2014年1月—2016年12月潜江市中心医院收治的结核性胸膜炎患者120例作为研究对象,以随机数字表法分为观察组和对照组,每组60例.两组患者均给予全身常规抗结核联合微创胸腔置管引流的基础治疗.在此基础上,观察组患者给予胸腔内交替注射尿激酶、异烟肼和地塞米松;对照组患者给予胸腔内注射尿激酶.观察两组患者的临床疗效、临床症状消失时间、胸腔积液消失时间、胸膜厚度、用力肺活量及并发症发生情况.结果:两组患者总有效率的差异有统计学意义(P0.05).两组患者并发症发生率的差异无统计学意义(P>0.05).结论:在常规抗结核治疗基础上,于微创胸腔置管内交替注射尿激酶、异烟肼和地塞米松治疗结核性胸膜炎的疗效显著,能缩短患者临床症状消失时间及胸腔积液消失时间,减少胸膜厚度.%OBJECTIVE: To probe into the clinical efficacy of minimally invasive intrapleural injection of urokinase , isoniazid and dexamethasone in treatment of tuberculous pleurisy . METHODS: 120 patients with tuberculous pleurisy admitted into Qianjiang Central Hospital from Jan .2014 to Dec.2016 were extracted to be divided into observation group and control group via the random number table , with 60 cases in each.Two groups were given outine anti tuberculosis combined with minimal invasive thoracic drainage , based on which , the observation group was treated with intrapleural injection of urokinase , isoniazid and dexamethasone , while the control group received intrapleural injection of urokinase .The clinical efficacy , disappearance time of clinical symptoms and pleural effusion , pleural thickness , forced vital capacity ( FVC ) and complication rate of two groups were observed . RESULTS:There was statistically significant difference between two groups in the total effective rate (P0.05 ) .And the complication rate of two groups was not statistically significant ( P >0.05 ) .CONCLUSIONS: Based on the conventional treatment , intralumen injection of urokinase , isoniazid and dexamethasone in treatment of tuberculous pleurisy has significant efficacy , which can shorten the time of pleural effusion absorption and reduce the pleura thickness , reduce the pleural thickness .
展开▼
